Literature DB >> 17337138

DSC and EPR investigations on effects of cholesterol component on molecular interactions between paclitaxel and phospholipid within lipid bilayer membrane.

Lingyun Zhao1, Si-Shen Feng, Nikolai Kocherginsky, Iouri Kostetski.   

Abstract

Differential scanning calorimetry (DSC) and electron paramagnetic resonance spectroscopy (EPR) were applied to investigate effects of cholesterol component on molecular interactions between paclitaxel, which is one of the best antineoplastic agents found from nature, and dipalmitoylphosphatidylcholine (DPPC) within lipid bilayer vesicles (liposomes), which could also be used as a model cell membrane. DSC analysis showed that incorporation of paclitaxel into the DPPC bilayer causes a reduction in the cooperativity of bilayer phase transition, leading to a looser and more flexible bilayer structure. Including cholesterol component in the DPPC/paclitaxel mixed bilayer can facilitate the molecular interaction between paclitaxel and lipid and make the tertiary system more stable. EPR analysis demonstrated that both of paclitaxel and cholesterol have fluidization effect on the DPPC bilayer membranes although cholesterol has more significant effect than paclitaxel does. The reduction kinetics of nitroxides by ascorbic acid showed that paclitaxel can inhibit the reaction by blocking the diffusion of either the ascorbic acid or nitroxide molecules since the reaction is tested to be a first order one. Cholesterol can remarkably increase the reduction reaction speed. This research may provide useful information for optimizing liposomal formulation of the drug as well as for understanding the pharmacology of paclitaxel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17337138     DOI: 10.1016/j.ijpharm.2007.01.045

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  Rational Design of Cholesterol Derivative for Improved Stability of Paclitaxel Cationic Liposomes.

Authors:  Jasmin Monpara; Chryso Kanthou; Gillian M Tozer; Pradeep R Vavia
Journal:  Pharm Res       Date:  2018-03-08       Impact factor: 4.200

2.  Infrared Spectroscopic Study of Multi-Component Lipid Systems: A Closer Approximation to Biological Membrane Fluidity.

Authors:  Maria C Klaiss-Luna; Marcela Manrique-Moreno
Journal:  Membranes (Basel)       Date:  2022-05-20

3.  Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery.

Authors:  Guangxi Zhai; Jun Wu; Guangya Xiang; Wenxue Mao; Bo Yu; Hong Li; Longzhu Piao; L James Lee; Robert J Lee
Journal:  J Nanosci Nanotechnol       Date:  2009-03

4.  In Vitro Anti/Pro-oxidant Activities of R. ferruginea Extract and Its Effect on Glioma Cell Viability: Correlation with Phenolic Compound Content and Effects on Membrane Dynamics.

Authors:  Desirée Magalhães Dos Santos; Camila Valesca Jardim Rocha; Elita Ferreira da Silveira; Marcelo Augusto Germani Marinho; Marisa Raquel Rodrigues; Nichole Osti Silva; Ailton da Silva Ferreira; Neusa Fernandes de Moura; Gabriel Jorge Sagrera Darelli; Elizandra Braganhol; Ana Paula Horn; Vânia Rodrigues de Lima
Journal:  J Membr Biol       Date:  2018-02-08       Impact factor: 1.843

5.  Interaction of Docetaxel with Phosphatidylcholine Membranes: A Combined Experimental and Computational Study.

Authors:  Elisa Aranda; José A Teruel; Antonio Ortiz; María Dolores Pérez-Cárceles; Francisco J Aranda
Journal:  J Membr Biol       Date:  2022-02-17       Impact factor: 2.426

6.  Preparation of DPPC liposomes using probe-tip sonication: Investigating intrinsic factors affecting temperature phase transitions.

Authors:  Monica D Rieth; Andrew Lozano
Journal:  Biochem Biophys Rep       Date:  2020-04-20

7.  Co-Encapsulation of Fisetin and Cisplatin into Liposomes for Glioma Therapy: From Formulation to Cell Evaluation.

Authors:  Morgane Renault-Mahieux; Victoire Vieillard; Johanne Seguin; Philippe Espeau; Dang Tri Le; René Lai-Kuen; Nathalie Mignet; Muriel Paul; Karine Andrieux
Journal:  Pharmaceutics       Date:  2021-06-26       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.